

10 September 2026

An \$8.5M Boost for Australian Infectious Disease Prevention Innovators – Biointellect Venturer Round 2 EOIs Open Soon!

Biointellect Venturer – Building and strengthening commercialisation capability, partnerships and investment readiness for Australian Infectious Disease Prevention Innovation.

Sydney, Australia – Biointellect Venturer, Australia's national incubator for infectious disease innovation, is set to launch Round 2 of its funding to support a second cohort of Australian innovators later this month – Expressions of Interest (EOIs) for Round 2 open Monday 21 September 2026 at 9:00 AM AEST. Round 2 offers total funding of AUD \$8.5 million and will focus on technologies for the prevention of infectious disease, aiming to materially advance innovation in this critical health sector. EOIs close Friday 16 October 2026 at 4:00 PM AEDT.

[Biointellect Venturer](#) was established with \$32.9 million in funding from the Australian Government, through the Medical Research Future Fund (MRFF) 2024 BioMedTech Incubator Grant Opportunity. The funding enables Biointellect to support the advancement of high-potential infectious disease innovations. Successful companies from Round 1 were announced at the Australian Vaccine Value Chain Conference, held recently in Sydney.

Infectious diseases remain among the world's greatest health challenges. New strains of influenza and COVID-19 continue to emerge each year, while long-standing diseases such as tuberculosis and other bacterial infections are becoming increasingly difficult to treat. The ongoing threat of emerging pathogens and future pandemics highlights the importance of investing in innovative approaches to prevent infectious diseases. For Australia, building sovereign capability in this area is critical to support national health security and pandemic preparedness.

However, research alone is not enough. Biointellect Venturer was established to nurture promising scientific discoveries through the commercialisation process, enabling them to progress from the laboratory to the patients and communities that need them. The program brings together Biointellect's deep expertise in development and commercialisation strategy, regulatory pathways, market access and global partnering to support innovators to progress from promising science toward investment-ready ventures.

Biointellect Venturer, General Manager, Danielle Shand, says Round 2 offers another important opportunity to identify and accelerate high-potential Australian innovations for infectious disease prevention.

"We are looking for Australian SMEs, research teams and innovators with novel and differentiated solutions, strong science, a clear development pathway and the potential to deliver meaningful public health impact. Biointellect Venturer combines substantial non-dilutive funding with tailored, hands-on support, strategic guidance and networks to help companies address critical development gaps, strengthen their commercialisation pathway and progress toward investment readiness," she said.

Biointellect, Chief Executive Officer, Leah Goodman says Australia has the scientific talent and innovative thinking needed to address some of the world's most pressing infectious disease challenges.

"It is important that we continue to strengthen the pipeline of technologies and companies capable of translating innovation into real-world health impact, and programs like Biointellect Venturer play a significant and valuable role in supporting this journey," she said.

Eoi opening period: Open 21 September 2026, 9:00 AM AEST, and close 16 October 2026, 4:00 PM AEDT.

To support Round 2 applicants, Biointelect Venturer will host an online **Information Session** on Thursday 24 September at 11:00 AM AEST and a **Grant Writing Workshop** on Wednesday 30 September at 11:00 AM AEST.

Round 2 is Biointelect Venturer's second and final cohort intake through the current MRFF-funded BioMedTech Incubator Grant Opportunity. There will be a dedicated follow-on/top-up funding round available to Rounds 1 and 2 cohorts to support the continued advancement of high-potential infectious disease innovations.

For further information about Round 2, Funding Guidelines and the Information Session and Grant Writing Workshop, visit: [Biointelect Venturer](#)

END

About Biointelect

Biointelect offers full-service CRO and commercialisation capabilities to help emerging biotech and medtech companies translate innovation into commercial success, which Biointelect Venturer, Australia's national incubator for infectious disease innovation, leverages fully for its mission. Drawing on expertise spanning research and development, clinical strategy and execution, regulatory affairs, market access, health economics, reimbursement and commercialisation planning, Biointelect provides both the technical delivery and strategic guidance required to progress products from concept and clinical development through to investment readiness, market adoption and patient impact. biointelect.com

About Biointelect Venturer

Biointelect Venturer is Australia's national incubator for infectious disease innovation, helping promising Australian scientific innovators accelerate their path from discovery to impact. Funded by the Australian Government's Medical Research Future Fund (MRFF) through the 2024 BioMedTech Incubator grant opportunity, Biointelect Venturer combines catalytic non-dilutive funding with commercialisation expertise, strategic guidance, networks and tailored support to progress early-stage innovations towards commercial and investment readiness. Managed and operated by Biointelect, the incubator builds on Biointelect's deep expertise and success in supporting early-stage biotech and medtech commercialisation. biointelect.com/biointelect-venturer/
For program enquiries: venturer@biointelect.com

Media Contacts:

Leah Goodman

Chief Executive Officer, Biointelect
lgoodman@biointelect.com

Danielle Shand

General Manager, Biointelect Venturer
dshand@biointelect.com